Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE

Bank of America Corp DE lifted its position in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) by 36.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 113,020 shares of the company’s stock after purchasing an additional 30,303 shares during the quarter. Bank of America Corp DE owned about 0.08% of Compass Therapeutics worth $164,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in Compass Therapeutics by 31.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after buying an additional 11,326 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock worth $404,000 after acquiring an additional 56,000 shares in the last quarter. Barclays PLC raised its stake in shares of Compass Therapeutics by 13.2% in the 4th quarter. Barclays PLC now owns 192,766 shares of the company’s stock valued at $279,000 after acquiring an additional 22,521 shares during the period. BNP Paribas Financial Markets acquired a new position in shares of Compass Therapeutics during the 4th quarter valued at $27,000. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Compass Therapeutics by 512.5% during the 4th quarter. JPMorgan Chase & Co. now owns 272,328 shares of the company’s stock valued at $395,000 after acquiring an additional 227,864 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Insider Buying and Selling at Compass Therapeutics

In other news, Director Carl L. Gordon sold 3,571,428 shares of Compass Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total value of $5,678,570.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares in the company, valued at approximately $32,340. The trade was a 2,000.00% increase in their position. The disclosure for this purchase can be found here. 29.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and increased their target price for the company from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Leerink Partnrs raised Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, April 1st. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, Piper Sandler began coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price objective for the company. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $13.13.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $2.41 on Monday. Compass Therapeutics, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $4.08. The business has a 50 day moving average price of $2.00 and a two-hundred day moving average price of $2.20. The firm has a market cap of $333.26 million, a PE ratio of -6.51 and a beta of 1.41.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.12). On average, analysts anticipate that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Compass Therapeutics Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.